TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed the Final (28 day) follow-up visit in Study ALX0681-C301.~2. \>= 18 years of age at the time of signing the informed consent form.~3. Provided informed consent prior to initiation of any study specific activity/procedure.~Exclusion Criteria:~1. Not being able/willing to comply with the study protocol procedures.~2. Currently enrolled in a clinical study with another investigational drug or device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- caplacizumab (Type: EXPERIMENTAL): Participants who completed study ALX0681-C301 (NCT02553317) with standard of care (plasma exchange \[PE\], corticosteroid and other immunosuppressive agents) or caplacizumab with PE and immunosuppressive agents were enrolled in study LTS16371. Participants upon each recurrence of aTTP in LTS16371 and not meeting any criteria (namely: pregnancy, history of severe and/or serious hypersensitivity reaction to investigational medicinal product \[IMP\], withdrawal before receiving IMP, received more than 1 PE) were treated with caplacizumab initial 10 milligrams (mg) intravenous dose followed by a daily 10 mg subcutaneous injections during the period of PE and for 30 days after stop of PE (and eventually 28-day extension period, if needed). Participants with or without recurrence were followed up twice yearly up to maximum of 36 months in LTS16371.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years old~* Acute Ischemic Stroke on the middle cerebral artery territory~* Treatment with iv tPA in the first 3 hours from symptoms onset~Exclusion Criteria:~* Modified Rankin Scale more or equal to 2~* Infectious, inflammatory, neoplastic or hematologic disease~* Anemia (Hto\<34% or Hb\<10g/dl)~* Previous renal failure~* Previous treatment with oral iron supplement~* Minor stroke (NIHSS less than 4), lacunar or posterior territory~* Alcohol consumption (more than 40mg/Kg)~* Pregnancy~* Participation in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1. Deferoxamine (Type: ACTIVE_COMPARATOR): Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
- 2. Placebo (Type: PLACEBO_COMPARATOR): Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I or II~* Body mass index (BMI) ≥ 35 kg/cm-2~Exclusion Criteria:~* Patients with gastrointestinal disorders,~* Patients with significant major organ disease,~* Patients received antidepressant drugs,~* Patients received an anti-emetic drug within 48 h before surgery,~* Patients on treatment with systemic glucocorticoids within 4 weeks before surgery.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Aprepitant/Dexamethasone Group (Type: ACTIVE_COMPARATOR): None
- Mertazepine /Dexamethasone Group (Type: ACTIVE_COMPARATOR): None
- Dexamethasone Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Increased risk of SARS-CoV-2 infection~* Medically stable~Exclusion Criteria:~* confirmed or suspected immunosuppressive or immunodeficient state~* significant disease, disorder, or finding~* Prior or concomitant vaccine therapy for COVID-19

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: t

Study Arms:
- AZD1222 (Type: EXPERIMENTAL): Approximately 20,000 participants randomized to the AZD1222 arm
- Placebo (Type: PLACEBO_COMPARATOR): Approximately 10,000 participants randomized to the saline placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 18 years of age at time of screening.~* Willingness and ability to comply with study procedures and visit schedules and able to follow oral and written instructions.~* A standing knee radiograph showing a K-L grade of 2 to 4~* Body mass index ≤ 40 kg/m2~* A qualifying WOMAC LK 3.1 pain subscale total score~* Signed an ethics committee-reviewed and approved informed consent form.~Exclusion Criteria:~* Presence of clinically observed active infection in the index knee~* Presence of symptomatic OA in the non-study knee at screening~* Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; HIV, viral hepatitis; chondrocalcinosis, Paget's disease, or villonodular synovitis~* Diagnosed with leukemia, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment~* Presence of venous or lymphatic stasis in the index leg~* A history of local anesthetic allergy~* Previously documented failed treatment with nSTRIDE APS or Synvisc One

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nSTRIDE APS (Type: ACTIVE_COMPARATOR): The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
- Synvisc-One (Type: ACTIVE_COMPARATOR): Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects able and willing to sign the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Informed Consent Form (ICF)~2. Male or female subjects of non-child-bearing potential aged ≥ 40 years~3. Subjects with a chest HRCT performed within 12 months prior to screening~4. Subjects with IPF diagnosed by a multidisciplinary team~5. Subjects with: a. forced vital capacity (FVC) ≥50% predicted of normal AND b. Diffusing capacity for the lungs for carbon monoxide (DLCO) ≥ 30% predicted of normal corrected for hemoglobin~6. Subjects with a forced expiratory volume in 1 second (FEV1)/FVC (Tiffeneau-Pinelli index) ratio ≥ 0.70 (based on pre-bronchodilator spirometry~7. Subjects on stable supportive care~8. Subjects in stable condition~Exclusion Criteria:~1. Subjects with know hypersensitivity to any of the study drug ingredients~2. Subjects with a history of or current immunosuppressive condition~3. Subjects with a history of malignancy within the past 5 years~4. Subjects with clinically significant abnormalities on ECG~5. Subjects with acute IPF exacerbation within 6 weeks prior to screening~6. Subjects with a lower respiratory tract infection requiring antibiotics with 4 weeks prior to screening~7. Smoking within 3 months pre-screening~8. Interstitial lung disease~9. History of lung volume reduction surgery or lung transplant~10. Unstable cardiac or pulmonary disease other than IPF within 6 months prior to screening~11. Subjects with abnormal liver function~12. Subjects with abnormal renal function

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLPG1690 600 mg once daily (QD) (Type: EXPERIMENTAL): None
- Placebo QD (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Articulating Enseal Versus Ligasure Energy Devices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Able and willing to provide informed consent~* Undergoing total laparoscopic hysterectomy~Exclusion Criteria:~* Under 18 years of age~* Severe endometriosis or adhesions requiring \>15min of adhesiolysis prior to beginning hysterectomy~* Unsafe to use energy device due to decreased visualization or any other reason deemed to be unsafe by the surgeon intra-operative decision to convert to laparotomy prior to use of energy device~* Current diagnosis of uterine, tubal ovarian or cervical malignancy.~* Patients who cannot read/understand English.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- articulating Enseal (Type: ACTIVE_COMPARATOR): This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
- Ligasure device (Type: ACTIVE_COMPARATOR): This group of women undergoing hysterectomy is randomized to the Ligasure energy device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Repeated, spontaneous epistaxis in a known Rendu Osler patient who wants global caring, these must be daily epistaxis (\> 28 a month) or a total amount of 60 minutes of bleeding a month (50 % Rendu-Osler patients bleed before 20 and 99 % at 50 when penetrance is complete).~* Good completion of the grid of control by recording the number and duration of epistaxis over a period of three month.~Exclusion Criteria:~* Rendu Osler syndrome with specific phenotype : absence of epistaxis or occasional epistaxis, no need for particular care.~* Maintained expectations of an ENT treatment of epistaxis in a delay of three months.~* Incapacity of detailing the number of epistaxis, especially, at least, within three months before entering the study.~* No informed consent obtained after informing the patient on his participation to the study.~* Expected lack of observance because of an incapacity to compel to the daily treatment.~* Formal indication to Tranexamic Acid (angioneurotic oedema as a disease modifying treatment of 3 to 4 g/ day).~* Contra-indications to Tranexamic acid: history of convulsion, arterial or veinous thrombosis, , positivity of veinous echo doppler of the inferior limbs; Serum creatinine \> 250 µmol/l.~N.B. Cases of bad observance are not frequent, patients being highly concerned with a treatment to reduce their discomfort and anaemia. They are more likely ready to move to a centre insuring this handling. Nevertheless, lack of observance will be detected over a period of 15 days of placebo in simple blind, before randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed renal cell carcinoma of clear cell histology with metastases~* Evidence of measurable disease by radiographic technique~* Eastern Cooperative Oncology Group \[ECOG\] performance status of 0 or 1~Exclusion Criteria:~* Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC~* History of or known brain metastases~* Serious acute or chronic illness or recent history of significant cardiac abnormality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled for bunion surgery~Exclusion Criteria:~* daily opioid use~* drug or alcohol abuse~* pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sufentanil NanoTab 20 mcg (Type: EXPERIMENTAL): Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
- Sufentanil NanoTab 30 mcg (Type: EXPERIMENTAL): Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
- Placebo NanoTab (Type: PLACEBO_COMPARATOR): Placebo NanoTab as needed every 60 minutes for 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium / Respimat One-Year Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
None

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tiotropium Respimat 5mcg (Tio R5) (Type: OTHER): None
- Tiotropium Respimat 10mcg (Tio R10) (Type: OTHER): None
- Placebo (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients at least 18 years old planning to undergo an elective colonoscopy.~Exclusion Criteria:~1. Patients who are allergic or intolerant to any on the study drugs.~2. Pregnant patients.~3. Patients who required multiple day colon preparation in the past.~4. Patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon would not be considered elective colonoscopies and are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Nulytely (Type: ACTIVE_COMPARATOR): Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
- Gatorade/Miralax + Placebo (Type: EXPERIMENTAL): Gatorade 64 oz (1/2 gallon), Miralax 306 g and a placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and placebo at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
- Gatorade/Miralax + Bisacodyl (Type: EXPERIMENTAL): Gatorade 64 oz (1/2 gallon), Miralax 306 g and Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and Bisacodyl 10 mg at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gel-200 Versus Placebo in Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of painful, symptomatic tibio-femoral osteoarthritis of the knee (Grade 1-3 on Kellgren - Lawrence (K-L) score).~Exclusion Criteria:~* Subjects with Grade 4 on K-L score~* Subjects with inflammatory diseases of the knee other than osteoarthritis such as rheumatoid arthritis~* Serious systemic diseases~* Female subjects who are pregnant or lactating

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Gel-200 (Type: EXPERIMENTAL): None
- PBS (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telehealth Delivery of Treatment for Sleep Disturbances in Young Children With Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Both genders \>2 and \<7 years of age~2. Clinical diagnosis of ASD corroborated by the Modified Checklist for Autism in Toddlers169 or the Social Communication Questionnaire.170~3. Score of \>5 on the CSI and a Clinical Global Impression Severity (CGI-S) score of Moderate or greater.~4. Medication and supplement free or on stable medication or supplements (no changes in the past 6 weeks and no planned changes for 16 weeks).~5. Parental proficiency in spoken and written English language.~Exclusion Criteria:~1. Children with a serious medical condition or a known or suspected medical cause for sleep disturbances (e.g., nocturnal seizures, unresolved gastrointestinal problems such as reflux or constipation).~2. Children with a psychiatric disorder or serious behavioral problems requiring immediate treatment.~3. Children with known or suspected sleep apnea, restless legs, or periodic limb movements during sleep, or a circadian-based sleep disorder (e.g. delayed or advanced sleep phase syndrome) based on history and all available information.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Sleep Parent Training (Type: EXPERIMENTAL): The five SPT sessions (each 60-90 minutes in duration) are individually delivered over 10-week virtually (HIPAA compliant video-chat). After Session A, session order may be adjusted to address child-specific problems. One-on-one delivery of SPT permits flexibility for child-specific problems within the program.
- Sleep Parent Education (Type: ACTIVE_COMPARATOR): SPE consists of five 60-90 minute sessions, delivered individually over 10 weeks. SPE provides useful information to families of young children with ASD and sleep problems. Session A is designed to develop rapport. The sleep hygiene session (Session B) has been modeled from the RUBI manual. The other sessions include a systematic presentation on several relevant topics. An example of a SPE session is provided in the Intervention section. This condition is intended to parallel what would be offered in typical care, but by telehealth, where a parent might be educated about ASD as well as attend an outpatient appointment at a sleep clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete